About Careers Internship MedBlog Contact us

New Drug Promises Hope for Alzheimer's Patients

by VR Sreeraman on July 30, 2008 at 4:22 PM
 New Drug Promises Hope for Alzheimer's Patients

Scientists in Britain have developed a drug which could represent a major breakthrough in treatment for people with Alzheimer's disease.

The drug, Rember, targets the build-up of tau protein tangles which form inside the brain nerve cells of people with Alzheimer's. These tangles destroy nerve cells linked to memory, causing forgetfulness.


Professor Claude Wischik of Aberdeen University in northeast Scotland, who co-founded the company which created the drug, hailed the results as "the most significant development in the treatment of the tangles since Alois Alzheimer discovered them in 1907".

Experts have welcomed the findings but say bigger trials are needed to confirm the drug's effects and check it is safe.

An initial study into the drug's effectiveness focused on 321 people with mild and moderate Alzheimer's in Britain and Singapore.

Those on the drug experienced an 81 percent reduction in mental decline after 50 weeks, compared to a placebo group, researchers said.

Reacting to the findings, Professor Clive Ballard, head of research at Britain's Alzheimer's Society, said: "This first modestly-sized trial in humans is potentially exciting... however, we are not there yet.

"Larger scale trials are now needed to confirm the safety of this drug and establish how far it could benefit the thousands of people living with this devastating disease."

Alzheimer's is a degenerative brain disorder which causes problems with memory and behaviour, for which there is currently no cure. It affects around 350,000 people in Britain alone.

The findings were presented at the International Conference on Alzheimer's Disease in Chicago in the United States.

Source: AFP
Font : A-A+



Recommended Readings

Latest Drug News

Projected Growth: Psychedelic Drug Market Anticipated to Hit $7.2 Billion by 2029
The psychedelic market set for remarkable growth, projected to hit $7.2B by 2029 with a strong 55% CAGR.
Promising ALS Drug Candidate Extends Lifespan
The study explores whether CDNF could influence the progression of ALS in rodent models and to elucidate the mechanism through which it operates.
Amoxicillin-Calvulanate Vs Amoxicillin Preference in Child Sinusitis Treatment
Amoxicillin-clavulanate use in acute sinusitis patients is associated with a higher incidence of adverse events.
ADHD Medication Errors Surge by Nearly 300%
Professionals advocate for enhanced education of patients and caregivers, and creation of more effective child-resistant systems for monitoring ADHD medication.
Unknown Medication Side Effects Reported by 52% of Indian Families
In June, WHO raised concerns about 7 Indian cough syrups after complaints from several countries about contamination and health issues.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close
Greetings! How can I assist you?MediBot

New Drug Promises Hope for Alzheimer's Patients Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests